The potential role of Epstein-Barr Virus in breast cancer development.


Journal

Cellular and molecular biology (Noisy-le-Grand, France)
ISSN: 1165-158X
Titre abrégé: Cell Mol Biol (Noisy-le-grand)
Pays: France
ID NLM: 9216789

Informations de publication

Date de publication:
10 Dec 2023
Historique:
received: 30 09 2023
medline: 2 1 2024
pubmed: 2 1 2024
entrez: 30 12 2023
Statut: epublish

Résumé

We are looking into viral components that may contribute to breast cancer in order to find possible therapeutic targets. The Epstein-Barr virus (EBV), which has been found to cause nasopharyngeal carcinoma and Burkitt lymphoma, is thought to play a role in breast cancer. Our series' patients had a median age of 49, with nearly half being under the age of 49. T2 tumors (two to five centimeters in size) make up the vast majority of our collection (60%). Six percent of our patients showed lymph node involvement, with roughly the same number in the N1 and N2 stages (41.17% each). Only 17.64% of people are at the N3 stage. SBR II tumors were the most common (90%). Only 20% of patients have HER2 overexpression, whereas 73.33% have ER expression. EBV was found in 23.33% of breast carcinomas (7 cases/30) after oncoprotein LMP1 expression, but normal surrounding tissues tested negative. We discovered that overexpression of the HER2 protein is inversely related to the two HRs' expression. They have no relationship with EBV infection and, consequently, LMP1 expression. LMP1 expression was not shown to be linked with patient age, tumor grade, tumor size, or lymph node invasion.

Identifiants

pubmed: 38158663
doi: 10.14715/cmb/2023.69.13.36
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

241-249

Auteurs

Kahina Gouadfel (K)

Laboratoire LABAB. Université Mouloud Mammeri de Tizi-Ouzou, Algeria. khkbiochimie@hotmail.fr.

Abdelhalim Khenchouche (A)

Département de microbiologie, Faculté des sciences de la nature et de la vie, Université F.A. Sétif 1, Algeria. halim.khenchouche@gmail.com.

Sameh Rabea (S)

Department of Pharmaceutical Sciences. College of Pharmacy. AlMAAREFA University, Diriyah 13713 Riyadh, Saudi Arabia. houalitizi@yahoo.fr.

Ahd A Mansour (AA)

Medical Laboratory Science Department, Fakeeh College for Medical Sciences, P.O. Box 2537, Jeddah 21461, Saudi Arabia. houalitizi@yahoo.fr.

Mounir M Salem-Bekhit (MM)

Department of Pharmaceutics, College of Pharmacy, King Saud University, PO Box 2457, Riyadh 11451, Saudi Arabia. mbekhet@ksu.edu.sa.

Soraya Ouhida (S)

Laboratoire d'Anatomie pathologie. CHU Saadna Abdenour, Sétif, Algeria. sorayaouh@yahoo.fr.

Amine Msela (A)

Laboratoire LABAB. Université Mouloud Mammeri de Tizi-Ouzou, Algeria. vet915@gmail.com.

Mohamed M Salem (MM)

Faculty of Medicine, Huazhong University of Science and Technology, Wuhan, China. medozcockney@gmail.com.

Alessandro Erto (A)

Dipartiment odi Ingegneria Chimica, dei Materialie della Produzione Industriale,Università degli Studidi Napoli FedericoII, P.leTecchio, 80,80125 Napoli, Italy. aleserto@unina.it.

Yacine Benguerba (Y)

Laboratoire de Biopharmacie Et Pharmacotechnie (LPBT), Ferhat Abbas Setif 1 University, Setif, Algeria. benguerbayacine@yahoo.fr.

Karim Houali (K)

Laboratoire LABAB. Université Mouloud Mammeri de Tizi-Ouzou, Algeria. houalitizi@yahoo.fr.

Classifications MeSH